Prime medicine announces additional funding of up to $24 million from the cystic fibrosis foundation to advance prime editing treatments for cystic fibrosis

-- expanded funding builds on the initial agreement to accelerate development of prime editors for cystic fibrosis (cf) -- -- prime medicine to receive up to $24 million in additional funding from the cystic fibrosis foundation -- -- multiple hotspot prime editors may benefit more than 93% of people with cf -- cambridge, mass., july 16, 2025 (globe newswire) -- prime medicine, inc. (nasdaq: prme), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that the cystic fibrosis foundation (cf foundation) has agreed to provide the company with up to $24 million in additional funding to accelerate the development of prime editors designed to permanently correct cystic fibrosis-related lung disease.
PRME Ratings Summary
PRME Quant Ranking